PCT

(51) International Patent Classification 7:

A61K 38/17, 39/395, C12N

5/06, A61P 37/00

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau

(11) International Publication Number:

(43) International Publication Date:



WO 00/12113

9 March 2000 (09.03.00)

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

A3

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, IP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TI, TM, TT, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TI, TM, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, TT, LU, MC, NL, PT, SE), OAPI patent (BF, BI, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report. Before the expirator of the time limit for amending the claims and to be republished in the event of the receipt of amendments.
(88) Date of publication of the international search report: 29 June 2000 (29.06.00)
C-CELLS USING A CD2-BINDING AGENT, AND COMPOSITIONS
hocytes in a subject having a medical condition are described. The
10
+

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
ΑU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
ΑZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
вв	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP .	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côle d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	ΚZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Inte ional Application No

		PCT/US 99	/20026			
A. CLASSIF IPC 7	CATION OF SUBJECT MATTER A61K38/17 A61K39/395 C12N5/06	A61P37/00				
According to	International Patent Classification (IPC) or to both national classifica	ition and IPC				
B. FIELDS						
Minimum do	cumentation searched (classification system followed by classification ${ m CO7K}$	on symbols)				
	on searched other then minimum documentetion to the extent that si					
Electronic de	ita base consulted during the international search (name of data base).	se and, where practical, search terms used)			
C. DOCUME	NTS CONSIDERED TO BE RELEVANT					
Category *	Cliation of document, with indication, where appropriate, of the rele	evant pessages	Relevant to claim No.			
Х	EP 0 503 648 A (BIOGEN, INC.) 16 September 1992 (1992-09-16) cited in the application the whole document		1-63			
X ,	N. DAMLE ET AL.: "Stimulation of human T lymphocytes via the CD3 c molecules induces enhancement in endothelial permeability to macrowith participation of type-1 and intercellular adhesion pathways." EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 20, no. 9, September 1990 (1 pages 1995-2003, XP000892124 Weinheim, Germany	1-63				
	the whole document	-/	,			
X Further documents are listed in the continuation of box C. X Patent tamily members are listed in annex.						
Special categories of clad documents: The document bething the seems plate of the art which is not considered to be of particular relevance. The carrier of profits of the considered to be of particular relevance. The carrier of the particular relevance is to be of particular relevance. The carrier of the particular relevance is to be of particular relevance. The claimed invention in the particular relevance is the claimed invention of the particular relevance. The claimed invention is relevance to the claimed invention of the particular relevance, the claimed invention is relevance. The claimed invention of the particular relevance, the claimed invention of t						
	9 April 2000	08/05/2000	*			
Name and	mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31.651 epo ni,	Authorized officer				

Int ational Application No PCT/US 99/20026

W0 93 06852 A (BIOGEN, INC.) 15 April 1993 (1993-04-15) page 2, line 23 - line 24 examples claims K. YAMASHITA ET AL.: "A multimeric form of soluble recombinant sheep LFA-3 (CD58) inhibits human T-cell proliferation." IMMUNOLOGY, vol. 92, no. 1, September 1997 (1997-09), pages 39-44, XP002135989 Oxford, 6B abstract page 41, right-hand column, line 48 -page 43, left-hand column, line 14 page 43, right-hand column, line 7 - line 8 X. PENG ET AL.: "Ligation of CD2 provides a strong helper signal for the production of the type 2 cytokines interleukin-4 and -5 by memory T cells." CELLULAR IMMUNOLOGY, vol. 181, no. 1, 10 October 1997 (1997-10-10), pages 76-85, XPO08892106 New York, NY, USA abstract page 83, right-hand column, line 18 -page 84, left-hand column, line 23	ategory '	ation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication where appropriate, of the relevant passages		Relevant to claim No.
15 April 1993 (1993-04-15) page 2, line 23 - line 24 examples claims K. YAMASHITA ET AL.: "A multimeric form of soluble recombinant sheep LFA-3 (CD58) inhibits human T-cell proliferation." IMMUNOLOGY, vol. 92, no. 1, September 1997 (1997-09), pages 39-44, XP002135989 Oxford, 6B abstract page 41, right-hand column, line 48 -page 43, left-hand column, line 7 - line 8 K. Y. PENG ET AL.: "Ligation of CD2 provides a strong helper signal for the production of the type 2 cytokines interleukin-4 and -5 by memory T cells." CELLULAR IMMUNOLOGY, vol. 181, no. 1, 10 October 1997 (1997-10-10), pages 76-85, XPO00892106 New York, NY, USA X. J. HOFFMANN ET AL.: "Initiation and perpetuation of rat adjuvant arthritis is inhibited by the anti-CD2 monoclonal antibody (mAb) OX34." ANNALS OF RHEUMATIC DISEASES, vol. 56, no. 12, December 1997 (1997-12), pages 716-722, XP000892112 London, 68 44, 45, 49, 50, 54, 55, 59, 63				
of soluble recombinant sheep LFA-3 (CD58) inhibits human T-cell proliferation." IMMUNOLOGY, vol. 92, no. 1, September 1997 (1997-09), pages 39-44, XP002135989 Oxford, 6B abstract page 41, right-hand column, line 48 -page 43, left-hand column, line 7 - line 8 X X. PENG ET AL.: "Ligation of CD2 provides a strong helper signal for the production of the type 2 cytokines interleukin-4 and -5 by memory 1 cells." CELLULAR IMMUNOLOGY, vol. 181, no. 1, 10 October 1997 (1997-10-10), pages 76-85, XP000892106 New York, NY, USA X J. HOFFMANN ET AL.: "Initiation and perpetuation of rat adjuvant arthritis is inhibited by the anti-CD2 monoclonal antibody (mAb) 0X34." ANNALS OF RHEUMATIC DISEASES, vol. 56, no. 12, December 1997 (1997-12), pages 716-722, XP000892112 London, 6B S9-62 1-3.7.8, 1-3.7.8, 12-14, 18-20, 24.25, 24.25, 29.30, 34.35, 35, 36, 36, 37, 8, 39,40, 44,45, 49,50, 34,35, 39,40, 41,45, 42,5, 43,5, 39,40, 44,45, 49,50, 54,55, 59,63	X	15 April 1993 (1993-04-15) page 2, line 23 - line 24 examples		
pages 39-44, XP002135989 Oxford, GB abstract page 41, right-hand column, line 48 -page 43, left-hand column, line 7 - line 8 X	х	of soluble recombinant sheep LFA-3 (CD58) inhibits human T-cell proliferation."	**	
a strong helper signal for the production of the type 2 cytokines interleukin-4 and 18-205 by memory T cells." 24,25, 29,30, vol. 181, no. 1, 34,35, 10 October 1997 (1997-10-10), pages 76-85, 29,30, XP000892106 44,45, 49,50, 54,55, 59,63 abstract page 83, right-hand column, line 18 -page 84, left-hand column, line 23 1,37,8, 19reptuation of rat adjuvant arthritis is 13,14, 19hibited by the anti-CD2 monoclonal perpetuation of rat adjuvant arthritis is 13,14, 19hibited by the anti-CD2 monoclonal 18-20, antibody (mAb) 0X34 " 24,25, 29,30, vol. 56, no. 12, December 1997 (1997-12), 24,25, 29,30, 29,30, 29		pages 39-44, XP002135989 Oxford, GB abstract page 41, right-hand column, line 48 -page 43, left-hand column, line 14 page 43, right-hand column, line 7 - line		
page 83, right-hand column, line 18 -page 84, left-hand column, line 23 J. HOFFMANN ET AL.: "Initiation and perpetuation of rat adjuvant arthritis is 13,14, inhibited by the anti-CO2 monoclonal 18-20, antibody (mAb) 0X34." 24,25, ANNALS OF RHEUMATIC DISEASES, 29,30, vol. 56, no. 12, December 1997 (1997-12), pages 716-722, XP000892112 39,40, London, GB 44,45, 49,50, 54,55, 59,63 abstract page 718, right-hand column, line 14 - line 25 table 1	X	a strong helper signal for the production of the type 2 cytokines interleukin-4 and -5 by memory T cells.". CELLULAR IMMUNOLOGY, vol. 181, no. 1, 10 October 1997 (1997-10-10), pages 76-85, XP000892106		12-14, 18-20, 24,25, 29,30, 34,35, 39,40, 44,45, 49,50, 54,55,
perpetuation of rat adjuvant arthritis is inhibited by the anti-CD2 monoclonal 18-20, antibody (mAb) 0X34." 24,25, ANNALS OF RHEUMATIC DISEASES, vol. 56, no. 12, December 1997 (1997-12), pages 716-722, XP000892112 34,35, ay. 40, London, GB 44,45, 45,50, 54,55, 59,63 abstract page 718, right-hand column, line 14 - line 25 table 1		page 83, right-hand column, line 18 -page		
abstract page 718, right-hand column, line 14 - line 25 table 1	X	perpetuation of rat adjuvant arthritis is inhibited by the anti-CD2 monoclonal antibody (mAb) OX34." ANNALS OF RHEUMATIC DISEASES, vol. 56, no. 12, December 1997 (1997-12), pages 716-722, XP000892112		13,14, 18-20, 24,25, 29,30, 34,35, 39,40, 44,45, 49,50, 54,55,
-/		page 718, right-hand column, line 14 - line 25		
		-/		
		0.		
		0.0		

Inte Jonal Application No PCT/US 99/20026

		FC1/US 99/20026
C.(Continual	tion) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	G. MAJEAU ET AL.: "Mechanism of lymphocyte function-associated molecule 3-1g fusion proteins inhibition of T cell responses."	1-63
	THE JOURNAL OF IMMUNOLOGY, vol. 152, no. 6, 15 March 1994 (1994-03-15), pages 2753-2767, XP002135990 Baltimore, MD, USA abstract discussion	
A	Y. KASAHARA ET AL.: "Role of interleukin 6 for differential responsiveness of naive and memory CD4+ T cells in CD2-mediated activation." THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 172, no. 5, 1 November 1990 (1990-11-01), pages 1419-1424, XF000892122 New York, NY, USA abstract	1-63
A	P. HOLLSBERG ET AL.: "Increased protein kinase C activity in human memory T cells." CELLULAR IMMUNOLOGY, vol. 149, no. 1, June 1993 (1993-06), pages 170-179, XP000892120 New York, NY, USA abstract	1-63
Ρ,Χ	D. MAGILAVY ET AL.: "Pharmacodynamic effects of LFA3TIP (Amevive) in patients with chronic plaque psoriasis (CPP): Selective modulation of CD45RO+ lymphocytes." JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 112, no. 4, April 1999 (1999-04), page 609 XP002136039 Baltimore, MD, USA abstract 518	1-23, 59-63
		1
	94.	

...iernational application No.

INTERNATIONAL SEARCH REPORT

PCT/US 99/20026

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)					
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:						
1. X	Claims Nos.: because they relate to subject matter not required to be searched by this Authony, namely: Remark: Although claims 1-58 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.					
2.	Claims Nos.: because they relate to pairs of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful international Search can be carried out, specifically:					
з. 🗌	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).					
Box II	Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)					
This Int	ernational Searching Authority lound multiple inventions in this international application, as follows:					
•						
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.					
2.	As all searchable claims could be searched without effort ustifying an additional fee, this Authority did not invite payment of any additional fee.					
3.	As only some of the required additional search flees were timely paid by the applicant, this International Search Report covers only those claims for which lees were paid, specifically claims Nos.:					
4.	No required additional search lees were timely paid by the applicant. Consequently, this international Search Report is					
	restricted to the invention lirst mentioned in the claims; it is covered by claims Nos.:					
	The sales was a second of the sales was a se					
Remai	The additional search tees were accompanied by the applicant's protest.					
	No protest accompanied the payment of additional search fees.					

Information on patent family members

ints ional Application No PCT/US 99/20026

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 503648 A	16-09-1992	AU 660981 B AU 1754092 A CA 2081028 A HU 9500680 A KX 9203138 A SG 47766 A WO 9216622 A US 5728677 A US 5914111 A US 5928643 A US 5547853 A	13-07-1995 21-10-1992 13-09-1992 28-11-1995 01-09-1992 17-04-1998 01-10-1992 17-03-1998 22-06-1999 27-07-1999 20-08-1996
WO 9306852 A	15-04-1993	AU 678141 B AU 2889192 A AU 3525297 A CA 2120731 A EP 0607353 A EP 0786255 A JP 7502495 T	22-05-1997 03-05-1993 20-11-1997 15-04-1993 27-07-1994 30-07-1997 16-03-1995